Evaluation of oral small molecule drugs for the treatment of COVID-19 patients: a systematic review and network meta-analysis

References

• Umakanthan S, Sahu P, Ranade AV, et al. Origin, transmission, diagnosis and management of coronavirus disease 2019 (COVID-19). Postgrad Med J. 2020;96(1142):1–9. doi: 10.1136/postgradmedj-2020-138234.
   PubMed Web of Science ®Google Scholar
• Tian F, Yang R, Chen Z. Safety and efficacy of COVID-19 vaccines in children and adolescents: a systematic review of randomized controlled trials. J Med Virol. 2022;94(10):4644–4653. doi: 10.1002/jmv.27940.
   PubMed Web of Science ®Google Scholar
• WHO. Coronavirus disease COVID-19 [cited 2023 Jan 12]. Available from: https://www.who.int/emergencies/diseases/novel-coronavirus-2019
   Google Scholar
• PHOSP-COVID Collaborative Group. Clinical characteristics with inflammation profiling of long COVID and association with 1-year recovery following hospitalisation in the UK: a prospective observational study. Lancet Respir Med. 2022;10(8):761–775. doi: 10.1016/S2213-2600(22)00127-8.
   PubMed Web of Science ®Google Scholar
• Umakanthan S, Senthil S, John S, et al. The protective role of statins in COVID-19 patients: a retrospective observational study. Transl Med Commun. 2021;6(1):22. doi: 10.1186/s41231-021-00102-4.
   PubMedGoogle Scholar
• Huang L, Li X, Gu X, et al. Health outcomes in people 2 years after surviving hospitalisation with COVID-19: a longitudinal cohort study. Lancet Respir Med. 2022;10(9):863–876. doi: 10.1016/S2213-2600(22)00126-6.
   PubMed Web of Science ®Google Scholar
• Wulf Hanson S, Abbafati C, Aerts JG, Global Burden of Disease Long COVID Collaborators., et al. Estimated global proportions of individuals with persistent fatigue, cognitive, and respiratory symptom clusters following symptomatic COVID-19 in 2020 and 2021. JAMA. 2022;328(16):1604–1615. doi: 10.1001/jama.2022.18931.
   PubMed Web of Science ®Google Scholar
• Hsu CK, Chen CY, Chen WC, et al. Effect of sofosbuvir-based treatment on clinical outcomes of patients with COVID-19: a systematic review and meta-analysis of randomised controlled trials. Int J Antimicrob Agents. 2022;59(3):106545. doi: 10.1016/j.ijantimicag.2022.106545.
   PubMed Web of Science ®Google Scholar
• Wong CKH, Au ICH, Lau KTK, et al. Real-world effectiveness of molnupiravir and nirmatrelvir plus ritonavir against mortality, hospitalisation, and in-hospital outcomes among community-dwelling, ambulatory patients with confirmed SARS-CoV-2 infection during the omicron wave in Hong Kong: an observational study. Lancet. 2022;400(10359):1213–1222. doi: 10.1016/S0140-6736(22)01586-0.
   PubMed Web of Science ®Google Scholar
• Li G, De Clercq E. Therapeutic options for the 2019 novel coronavirus (2019-nCoV). Nat Rev Drug Discov. 2020;19(3):149–150. doi: 10.1038/d41573-020-00016-0.
   PubMed Web of Science ®Google Scholar
• Dejmek M, Konkoľová E, Eyer L, et al. Non-nucleotide RNA-dependent RNA polymerase inhibitor that blocks SARS-CoV-2 replication. Viruses. 2021;13(8):1585. doi: 10.3390/v13081585.
   PubMed Web of Science ®Google Scholar
• Yang H, Rao Z. Structural biology of SARS-CoV-2 and implications for therapeutic development. Nat Rev Microbiol. 2021;19(11):685–700. doi: 10.1038/s41579-021-00630-8.
   PubMed Web of Science ®Google Scholar
• Higgins JP, Altman DG, Gøtzsche PC, Cochrane Bias Methods Group; Cochrane Statistical Methods Group, et al. The Cochrane collaboration’s tool for assessing risk of bias in randomised trials. BMJ. 2011;343(2):d5928. doi: 10.1136/bmj.d5928.
   PubMed Web of Science ®Google Scholar
• McGavock J, Chauhan BF, Rabbani R, et al. Layperson-led vs professional-led behavioral interventions for weight loss in pediatric obesity: a systematic review and meta-analysis. JAMA Netw Open. 2020;3(7):e2010364. doi: 10.1001/jamanetworkopen.2020.10364.
   PubMed Web of Science ®Google Scholar
• Wang X, Wen D, He Q, et al. Effect of corticosteroids in patients with COVID-19: a Bayesian network meta-analysis. Int J Infect Dis. 2022;125:84–92. doi: 10.1016/j.ijid.2022.10.021.
   PubMed Web of Science ®Google Scholar
• Salanti G, Ades AE, Ioannidis JP. Graphical methods and numerical summaries for presenting results from multiple-treatment meta-analysis: an overview and tutorial. J Clin Epidemiol. 2011;64(2):163–171. doi: 10.1016/j.jclinepi.2010.03.016.
   PubMed Web of Science ®Google Scholar
• Ren Z, Luo H, Yu Z, et al. A randomized, open-label, controlled clinical trial of azvudine tablets in the treatment of mild and common COVID-19, a pilot study. Adv Sci (Weinh). 2020;7(19):e2001435. doi: 10.1002/advs.202001435.
   PubMedGoogle Scholar
• Fischer WA, Eron JJ, Holman W, et al. A phase 2a clinical trial of molnupiravir in patients with COVID-19 shows accelerated SARS-CoV-2 RNA clearance and elimination of infectious virus. Sci Transl Med. 2022;14(628):eabl7430. doi: 10.1126/scitranslmed.abl7430.
   PubMed Web of Science ®Google Scholar
• Caraco Y, Crofoot GE, Moncada PA. Phase 2/3 trial of molnupiravir for treatment of Covid-19 in nonhospitalized adults. NEJM Evid. 2022;1(2):1–10. doi: 10.1056/EVIDoa2100043.
   PubMedGoogle Scholar
• Jayk Bernal A, Gomes da Silva MM, Musungaie DB, et al. Molnupiravir for oral treatment of covid-19 in nonhospitalized patients. N Engl J Med. 2022;386(6):509–520. doi: 10.1056/NEJMoa2116044.
   PubMed Web of Science ®Google Scholar
• Khoo SH, FitzGerald R, Saunders G, et al. Molnupiravir versus placebo in unvaccinated and vaccinated patients with early SARS-CoV-2 infection in the UK (AGILE CST-2): a randomised, placebo-controlled, double-blind, phase 2 trial. Lancet Infect Dis. 2023;23(2):183–195. doi: 10.1016/S1473-3099(22)00644-2.
   PubMed Web of Science ®Google Scholar
• Butler CC, Hobbs FDR, Gbinigie OA, et al. Molnupiravir plus usual care versus usual care alone as early treatment for adults with COVID-19 at increased risk of adverse outcomes (PANORAMIC): an open-label, platform-adaptive randomised controlled trial. Lancet. 2023;401(10373):281–293. doi: 10.1016/S0140-6736(22)02597-1.
   PubMed Web of Science ®Google Scholar
• Zou R, Peng L, Shu D, et al. Antiviral efficacy and safety of molnupiravir against omicron variant infection: a randomized controlled clinical trial. Front Pharmacol. 2022;13:939573. doi: 10.3389/fphar.2022.939573.
   PubMedGoogle Scholar
• Cao Z, Gao W, Bao H, et al. VV116 versus Nirmatrelvir-Ritonavir for oral treatment of covid-19. N Engl J Med. 2023;388(5):406–417. doi: 10.1056/NEJMoa2208822.
   PubMed Web of Science ®Google Scholar
• Hammond J, Leister-Tebbe H, Gardner A, et al. Oral nirmatrelvir for high-risk, nonhospitalized adults with covid-19. N Engl J Med. 2022;386(15):1397–1408. doi: 10.1056/NEJMoa2118542.
   PubMed Web of Science ®Google Scholar
• Watson OJ, Barnsley G, Toor J, et al. Global impact of the first year of COVID-19 vaccination: a mathematical modelling study. Lancet Infect Dis. 2022;22(9):1293–1302. doi: 10.1016/S1473-3099(22)00320-6.
   PubMed Web of Science ®Google Scholar
• Umakanthan S, Patil S, Subramaniam N, et al. COVID-19 vaccine hesitancy and resistance in India explored through a population-based longitudinal survey. Vaccines (Basel). 2021;9(10):1064. doi: 10.3390/vaccines9101064.
   PubMed Web of Science ®Google Scholar
• Tian F, Chen Z, Zeng Y, et al. Prevalence of use of potentially inappropriate medications among older adults worldwide: a systematic review and meta-analysis. JAMA Netw Open. 2023;6(8):e2326910. doi: 10.1001/jamanetworkopen.2023.26910.
   PubMed Web of Science ®Google Scholar
• Umakanthan S, Bukelo MM, Gajula SS. The commonwealth Caribbean COVID-19: regions resilient pathway during pandemic. Front Public Health. 2022;10:844333. doi: 10.3389/fpubh.2022.844333.
   PubMed Web of Science ®Google Scholar
• Reynolds CJ, Pade C, Gibbons JM, et al. Immune boosting by B.1.1.529 (Omicron) depends on previous SARS-CoV-2 exposure. Science. 2022;377(6603):eabq1841. doi: 10.1126/science.abq1841.
   PubMed Web of Science ®Google Scholar
• National Health Commission of the People’s Republic of China. Scheme for diagnosis and treatment of SARS-CoV-2 (The 9th Trial Edition) [cited 2023 Feb 16]. Available from: http://www.gov.cn/zhengce/zhengceku/2022-03/15/content_5679257.htm
   Google Scholar
• Tian F, Chen Z, Feng Q. Nirmatrelvir-ritonavir compared with other antiviral drugs for the treatment of COVID-19 patients: a systematic review and meta-analysis. J Med Virol. 2023;95(4):e28732. doi: 10.1002/jmv.28732.
   PubMed Web of Science ®Google Scholar
• National Health Commission of the People’s Republic of China. Scheme for diagnosis and treatment of SARS-CoV-2 (The 10th Trial Edition) [cited 2023 Jan 12]. Available from: http://www.nhc.gov.cn/ylyjs/pqt/202301/32de5b2ff9bf4eaa88e75bdf7223a65a.shtml
   Google Scholar
• Cully M. A tale of two antiviral targets – and the COVID-19 drugs that bind them. Nat Rev Drug Discov. 2022;21(1):3–5. doi: 10.1038/d41573-021-v00202-8.
   PubMed Web of Science ®Google Scholar
• Rahmah L, Abarikwu SO, Arero AG, et al. Oral antiviral treatments for COVID-19: opportunities and challenges. Pharmacol Rep. 2022;74(6):1255–1278. doi: 10.1007/s43440-022-00388-7.
   PubMed Web of Science ®Google Scholar
• Heskin J, Pallett SJC, Mughal N, et al. Caution required with use of ritonavir-boosted PF-07321332 in COVID-19 management. Lancet. 2022;399(10319):21–22. doi: 10.1016/S0140-6736(21)02657-X.
   PubMed Web of Science ®Google Scholar
• Robert FS. A prominent virologist warns COVID-19 pill could unleash dangerous mutants. Others see little cause for alarm [cited 2022 Oct 6]. Available from: https://www.science.org/content/article/prominent-virologist-warns-covid-19-pill-could-unleash-dangerous-mutants-others-see-little-cause-alarm
   Google Scholar